Please wait while the formulary information is being retrieved.
DRUG IMAGES
DDAVP 0.2 MG TABLET
DDAVP 0.1 MG TABLET
DDAVP 4 MCG/ML AMPUL
DDAVP 40 MCG/10 ML VIAL
The following indications for DDAVP (desmopressin acetate (non-refrigerated)) have been approved by the FDA:
Indications:
Hemophilia A
Nocturnal enuresis
Partial central diabetes insipidus
Von Willebrand's disease
Professional Synonyms:
Angiohemophilia
Congenital factor VIII deficiency disease
Constitutional thrombopathy
Partial ADH deficiency induced diabetes insipidus
Partial neurogenic diabetes insipidus
Partial neurohypophyseal diabetes insipidus
Partial pituitary diabetes insipidus
Partial vasopressin-sensitive diabetes insipidus
Pseudohemophilia
Vascular hemophilia
Von Willebrand disease
Willebrand-Juergens disease
Indications:
Hemophilia A
Nocturnal enuresis
Partial central diabetes insipidus
Von Willebrand's disease
Professional Synonyms:
Angiohemophilia
Congenital factor VIII deficiency disease
Constitutional thrombopathy
Partial ADH deficiency induced diabetes insipidus
Partial neurogenic diabetes insipidus
Partial neurohypophyseal diabetes insipidus
Partial pituitary diabetes insipidus
Partial vasopressin-sensitive diabetes insipidus
Pseudohemophilia
Vascular hemophilia
Von Willebrand disease
Willebrand-Juergens disease
The following dosing information is available for DDAVP (desmopressin acetate (non-refrigerated)):
For the management of neurohypophyseal diabetes insipidus, the usual adult maintenance dosage of desmopressin acetate recommended by the manufacturer is 10-40 mcg (0.1-0.4 mL or 1-4 sprays from the spray pump of a solution containing 0.1 mg/mL) given intranasally in 1-3 divided doses daily. Some clinicians have recommended an adult desmopressin acetate maintenance dosage of 5-40 mcg (0.05-0.4 mL of a solution containing 0.1 mg/mL). Most adults require 20 mcg daily administered in 2 divided doses in the morning and the evening.
In children 3 months to 12 years of age, the initial dose of desmopressin acetate is 5 mcg or less (0.05 mL of a solution containing 0.1 mg/mL) administered intranasally in the evening. In children 3 months to 12 years of age, the usual intranasal dosage is 5-30 mcg (0.05-0.3 mL of a solution containing 0.1 mg/mL) daily in a single evening dose or divided in 2 doses. About 25-33% of adults and children can be controlled with a single daily dose.
The lowest effective dosage should be used. Fluid intake should be restricted. (See Cautions: Precautions and Contraindications.)
If the drug is administered by subcutaneous or direct IV injection in adults or children 12 years of age or older for the management of diabetes insipidus, the usual maintenance dosage is 2-4 mcg daily given in 2 divided doses. The parenteral dosage for the management of diabetes insipidus in children younger than 12 years of age has not been established. Patients with diabetes insipidus being switched from intranasal to subcutaneous or IV administration of the drug should generally receive one-tenth their maintenance intranasal dosage parenterally.
The lowest effective parenteral dosage should be given. During long-term use, patients rarely may develop tolerance to the drug and require cautious increase in dosage to achieve an adequate therapeutic response. Fluid intake should be restricted.
.)
If oral desmopressin acetate is used for the management of diabetes insipidus in patients who previously received the drug intranasally, oral therapy should be initiated 12 hours after the last intranasal dose. The usual initial oral dosage of desmopressin acetate for adults and pediatric patients is 0.05 mg twice daily, and subsequent dosage should be adjusted according to response.
In clinical studies, the optimal dosage range for most patients was 0.1-0.8 mg daily given in divided doses.
Each dose should be adjusted separately for an adequate diurnal rhythm of water turnover. Total oral daily dosage should be increased or decreased in the range of 0.1-1.2
mg divided into 2 or 3 daily doses as needed to obtain adequate antidiuresis. Fluid intake should be restricted. (See Cautions: Precautions and Contraindications.)
In children 3 months to 12 years of age, the initial dose of desmopressin acetate is 5 mcg or less (0.05 mL of a solution containing 0.1 mg/mL) administered intranasally in the evening. In children 3 months to 12 years of age, the usual intranasal dosage is 5-30 mcg (0.05-0.3 mL of a solution containing 0.1 mg/mL) daily in a single evening dose or divided in 2 doses. About 25-33% of adults and children can be controlled with a single daily dose.
The lowest effective dosage should be used. Fluid intake should be restricted. (See Cautions: Precautions and Contraindications.)
If the drug is administered by subcutaneous or direct IV injection in adults or children 12 years of age or older for the management of diabetes insipidus, the usual maintenance dosage is 2-4 mcg daily given in 2 divided doses. The parenteral dosage for the management of diabetes insipidus in children younger than 12 years of age has not been established. Patients with diabetes insipidus being switched from intranasal to subcutaneous or IV administration of the drug should generally receive one-tenth their maintenance intranasal dosage parenterally.
The lowest effective parenteral dosage should be given. During long-term use, patients rarely may develop tolerance to the drug and require cautious increase in dosage to achieve an adequate therapeutic response. Fluid intake should be restricted.
.)
If oral desmopressin acetate is used for the management of diabetes insipidus in patients who previously received the drug intranasally, oral therapy should be initiated 12 hours after the last intranasal dose. The usual initial oral dosage of desmopressin acetate for adults and pediatric patients is 0.05 mg twice daily, and subsequent dosage should be adjusted according to response.
In clinical studies, the optimal dosage range for most patients was 0.1-0.8 mg daily given in divided doses.
Each dose should be adjusted separately for an adequate diurnal rhythm of water turnover. Total oral daily dosage should be increased or decreased in the range of 0.1-1.2
mg divided into 2 or 3 daily doses as needed to obtain adequate antidiuresis. Fluid intake should be restricted. (See Cautions: Precautions and Contraindications.)
Desmopressin acetate is administered intranasally, orally, by subcutaneous injection, direct IV injection, or slow IV infusion.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| DDAVP 4 MCG/ML AMPUL | Maintenance | Adults inject 0.25 milliliter (1 mcg) by subcutaneous route 2 times per day |
| DDAVP 40 MCG/10 ML VIAL | Maintenance | Adults inject 0.5 milliliter (2 mcg) by subcutaneous route 2 times per day |
| DDAVP 0.1 MG TABLET | Maintenance | Adults take 1 tablet (0.1 mg) by oral route 2 times per day |
| DDAVP 0.2 MG TABLET | Maintenance | Adults take 1 tablet (0.2 mg) by oral route 2 times per day |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| DESMOPRESSIN ACETATE 0.1 MG TB | Maintenance | Adults take 1 tablet (0.1 mg) by oral route 2 times per day |
| DESMOPRESSIN ACETATE 0.2 MG TB | Maintenance | Adults take 1 tablet (0.2 mg) by oral route 2 times per day |
| DESMOPRESSIN AC 4 MCG/ML VIAL | Maintenance | Adults inject 0.5 milliliter (2 mcg) by subcutaneous route 2 times per day |
| DESMOPRESSIN 40 MCG/10 ML VIAL | Maintenance | Adults inject 0.5 milliliter (2 mcg) by subcutaneous route 2 times per day |
| DESMOPRESSIN AC 4 MCG/ML AMPUL | Maintenance | Adults inject 0.25 milliliter (1 mcg) by subcutaneous route 2 times per day |
The following drug interaction information is available for DDAVP (desmopressin acetate (non-refrigerated)):
There are 2 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Desmopressin/Glucocorticoids SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Glucocorticoids increase the risk of hyponatremia.(1-4) CLINICAL EFFECTS: Concurrent use of glucocorticoids may increase the risk of hyponatremia with desmopressin.(1-4) PREDISPOSING FACTORS: Predisposing factors for hyponatremia include: polydipsia, renal impairment (eGFR < 50 ml/min/1.73m2), illnesses that can cause fluid/electrolyte imbalances, age >=65, medications that cause water retention and/or increase the risk of hyponatremia (carbamazepine, chlorpromazine, lamotrigine, loop diuretics, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants). PATIENT MANAGEMENT: The concurrent use of systemic or inhaled glucocorticoids with desmopressin is contraindicated.(1-4) Desmopressin may be initiated 3 days or 5 half-lives after glucocorticoid discontinuation, whichever is longer. If concurrent use is deemed medically necessary, make sure serum sodium levels are normal before beginning therapy and consider using the desmopressin nasal 0.83 mcg dose. Consider measuring serum sodium levels more frequently than the recommended intervals of: within 7 days of concurrent therapy initiation, one month after concurrent therapy initiation and periodically during treatment. Counsel patients to report symptoms of hyponatremia, which may include: headache, nausea/vomiting, feeling restless, fatigue, drowsiness, dizziness, muscle cramps, changes in mental state (confusion, decreased awareness/alertness), seizures, coma, and trouble breathing. Counsel patients to limit the amount of fluids they drink in the evening and night-time and to stop taking desmopressin if they develop a stomach/intestinal virus with nausea/vomiting or any nose problems (blockage, stuffy/runny nose, drainage).(1) DISCUSSION: In clinical trials of desmopressin for the treatment of nocturia, 4 of 5 patients who developed severe hyponatremia (serum sodium <= 125 mmol/L) were taking systemic or inhaled glucocorticoids. Three of these patients were also taking NSAIDs and one was receiving a thiazide diuretic.(2) Drugs associated with hyponatremia may increase the risk, including loop diuretics, carbamazepine, chlorpromazine, glucocorticoids, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants.(1,3-4) |
ADVAIR DISKUS, ADVAIR HFA, AGAMREE, AIRDUO DIGIHALER, AIRDUO RESPICLICK, AIRSUPRA, ALKINDI SPRINKLE, ALVESCO, ANALPRAM HC, ANUCORT-HC, ANUSOL-HC, ARMONAIR DIGIHALER, ARNUITY ELLIPTA, ASMANEX, ASMANEX HFA, BECLOMETHASONE DIPROPIONATE, BETA 1, BETALOAN SUIK, BETAMETHASONE ACETATE MICRO, BETAMETHASONE ACETATE-SOD PHOS, BETAMETHASONE DIPROPIONATE, BETAMETHASONE SOD PHOS-ACETATE, BETAMETHASONE SOD PHOS-WATER, BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE VALERATE, BREO ELLIPTA, BREYNA, BREZTRI AEROSPHERE, BSP 0820, BUDESONIDE, BUDESONIDE DR, BUDESONIDE EC, BUDESONIDE ER, BUDESONIDE MICRONIZED, BUDESONIDE-FORMOTEROL FUMARATE, BUPIVACAINE-DEXAMETH-EPINEPHRN, CELESTONE, CLOBETASOL PROPIONATE MICRO, CORTEF, CORTENEMA, CORTIFOAM, CORTISONE ACETATE, DEFLAZACORT, DEPO-MEDROL, DESONIDE MICRONIZED, DESOXIMETASONE, DEXABLISS, DEXAMETHASONE, DEXAMETHASONE ACETATE, DEXAMETHASONE ACETATE MICRO, DEXAMETHASONE INTENSOL, DEXAMETHASONE ISONICOTINATE, DEXAMETHASONE MICRONIZED, DEXAMETHASONE SOD PHOS-WATER, DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE-0.9% NACL, DMT SUIK, DOUBLEDEX, DULERA, EMFLAZA, EOHILIA, FLUNISOLIDE, FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE MICRO, FLUOCINONIDE MICRONIZED, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE HFA, FLUTICASONE PROPIONATE MICRO, FLUTICASONE-SALMETEROL, FLUTICASONE-SALMETEROL HFA, FLUTICASONE-VILANTEROL, HEMADY, HEMMOREX-HC, HEXATRIONE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE SOD SUCCINATE, HYDROCORTISONE-PRAMOXINE, KENALOG-10, KENALOG-40, KENALOG-80, LIDOCAINE-HYDROCORTISONE, LIDOCIDEX-I, MAS CARE-PAK, MEDROL, MEDROLOAN II SUIK, MEDROLOAN SUIK, METHYLPREDNISOLONE, METHYLPREDNISOLONE AC MICRO, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM SUCC, MILLIPRED, MILLIPRED DP, MOMETASONE FUROATE, ORAPRED ODT, ORTIKOS, PEDIAPRED, PREDNISOLONE, PREDNISOLONE ACETATE MICRONIZE, PREDNISOLONE MICRONIZED, PREDNISOLONE SODIUM PHOS ODT, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE, PREDNISONE INTENSOL, PREDNISONE MICRONIZED, PRO-C-DURE 5, PRO-C-DURE 6, PROCORT, PROCTOCORT, PROCTOFOAM-HC, PULMICORT, PULMICORT FLEXHALER, QVAR REDIHALER, RAYOS, SOLU-CORTEF, SOLU-MEDROL, SYMBICORT, TAPERDEX, TARPEYO, TRELEGY ELLIPTA, TRIAMCINOLONE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE MICRO, TRILOAN II SUIK, TRILOAN SUIK, UCERIS, VERIPRED 20, WIXELA INHUB, ZCORT, ZILRETTA, ZYPRAM |
| Desmopressin/Loop Diuretics SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Loop diuretics increase the risk of hyponatremia.(1-4) CLINICAL EFFECTS: Concurrent use of loop diuretics may increase the risk of hyponatremia with desmopressin.(1-4) PREDISPOSING FACTORS: Predisposing factors for hyponatremia include: polydipsia, renal impairment (eGFR < 50 ml/min/1.73m2), illnesses that can cause fluid/electrolyte imbalances, age >=65, medications that cause water retention and/or increase the risk of hyponatremia (carbamazepine, chlorpromazine, glucocorticoids, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants). PATIENT MANAGEMENT: The concurrent use of loop diuretics with desmopressin is contraindicated.(1-4) If concurrent use is deemed medically necessary, make sure serum sodium levels are normal before beginning therapy and consider using the desmopressin nasal 0.83 mcg dose. Consider measuring serum sodium levels more frequently than the recommended intervals of: within 7 days of concurrent therapy initiation, one month after concurrent therapy initiation and periodically during treatment. Counsel patients to report symptoms of hyponatremia, which may include: headache, nausea/vomiting, feeling restless, fatigue, drowsiness, dizziness, muscle cramps, changes in mental state (confusion, decreased awareness/alertness), seizures, coma, and trouble breathing. Counsel patients to limit the amount of fluids they drink in the evening and night-time and to stop taking desmopressin if they develop a stomach/intestinal virus with nausea/vomiting or any nose problems (blockage, stuffy/runny nose, drainage).(1) DISCUSSION: In clinical trials of desmopressin for the treatment of nocturia, 4 of 5 patients who developed severe hyponatremia (serum sodium <= 125 mmol/L) were taking systemic or inhaled glucocorticoids. Three of these patients were also taking NSAIDs and one was receiving a thiazide diuretic.(2) Drugs associated with hyponatremia may increase the risk, including loop diuretics, carbamazepine, chlorpromazine, glucocorticoids, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants.(1,3-4) |
BUMETANIDE, EDECRIN, ETHACRYNATE SODIUM, ETHACRYNIC ACID, FUROSCIX, FUROSEMIDE, FUROSEMIDE-0.9% NACL, LASIX, SOAANZ, TORSEMIDE |
There are 0 severe interactions.
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Desmopressin/Agents with Hyponatremia Risk SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Carbamazepine, chlorpromazine, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants increase the risk of hyponatremia.(1-3) CLINICAL EFFECTS: Concurrent use may increase the risk of hyponatremia with desmopressin.(1-3) PREDISPOSING FACTORS: Predisposing factors for hyponatremia include: polydipsia, renal impairment (eGFR < 50 ml/min/1.73m2), illnesses that can cause fluid/electrolyte imbalances, age >=65, medications that cause water retention and/or increase the risk of hyponatremia (glucocorticoids, loop diuretics). PATIENT MANAGEMENT: The concurrent use of agents with a risk of hyponatremia with desmopressin may increase the risk of hyponatremia. If concurrent use is deemed medically necessary, make sure serum sodium levels are normal before beginning therapy and consider using the desmopressin nasal 0.83 mcg dose. Consider measuring serum sodium levels more frequently than the recommended intervals of: within 7 days of concurrent therapy initiation, one month after concurrent therapy initiation and periodically during treatment. Counsel patients to report symptoms of hyponatremia, which may include: headache, nausea/vomiting, feeling restless, fatigue, drowsiness, dizziness, muscle cramps, changes in mental state (confusion, decreased awareness/alertness), seizures, coma, and trouble breathing. Counsel patients to limit the amount of fluids they drink in the evening and night-time and to stop taking desmopressin if they develop a stomach/intestinal virus with nausea/vomiting or any nose problems (blockage, stuffy/runny nose, drainage).(1) DISCUSSION: In clinical trials of desmopressin for the treatment of nocturia, 4 of 5 patients who developed severe hyponatremia (serum sodium <= 125 mmol/L) were taking systemic or inhaled glucocorticoids. Three of these patients were also taking NSAIDs and one was receiving a thiazide diuretic.(2) Drugs associated with hyponatremia may increase the risk, including loop diuretics, carbamazepine, chlorpromazine, glucocorticoids, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants.(1,3-4) |
ACCURETIC, ACETAMIN-CAFF-DIHYDROCODEINE, ACETAMINOPHEN-CODEINE, AMILORIDE-HYDROCHLOROTHIAZIDE, AMITRIPTYLINE HCL, AMLODIPINE-VALSARTAN-HCTZ, AMOXAPINE, ANAFRANIL, ANAPROX DS, ANJESO, APADAZ, ARTHROTEC 50, ARTHROTEC 75, ASA-BUTALB-CAFFEINE-CODEINE, ASCOMP WITH CODEINE, ATACAND HCT, ATENOLOL-CHLORTHALIDONE, AVALIDE, BELBUCA, BELLADONNA-OPIUM, BENAZEPRIL-HYDROCHLOROTHIAZIDE, BENICAR HCT, BENZHYDROCODONE-ACETAMINOPHEN, BISOPROLOL-HYDROCHLOROTHIAZIDE, BRIXADI, BROMFENAC SODIUM, BUPIVACAINE-KETOROLAC-KETAMINE, BUPRENORPHINE, BUPRENORPHINE HCL, BUPRENORPHINE-NALOXONE, BUTALB-ACETAMINOPH-CAFF-CODEIN, BUTORPHANOL TARTRATE, BUTRANS, CALDOLOR, CAMBIA, CANDESARTAN-HYDROCHLOROTHIAZID, CAPTOPRIL-HYDROCHLOROTHIAZIDE, CARBAMAZEPINE, CARBAMAZEPINE ER, CARBATROL, CARISOPRODOL-ASPIRIN-CODEINE, CELEBREX, CELECOXIB, CELEXA, CHLORDIAZEPOXIDE-AMITRIPTYLINE, CHLOROTHIAZIDE, CHLOROTHIAZIDE SODIUM, CHLORPROMAZINE HCL, CHLORTHALIDONE, CITALOPRAM HBR, CLOMIPRAMINE HCL, CODEINE PHOSPHATE, CODEINE SULFATE, COMBOGESIC, COMBOGESIC IV, CONSENSI, CONZIP, COXANTO, DAYPRO, DEMEROL, DESIPRAMINE HCL, DICLOFENAC, DICLOFENAC POTASSIUM, DICLOFENAC SODIUM, DICLOFENAC SODIUM ER, DICLOFENAC SODIUM MICRONIZED, DICLOFENAC SODIUM-MISOPROSTOL, DIFLUNISAL, DIHYDROCODEINE BITARTRATE, DILAUDID, DIOVAN HCT, DIPHENOXYLATE-ATROPINE, DISKETS, DIURIL, DOLOBID, DOXEPIN HCL, DSUVIA, DURAMORPH, EC-NAPROSYN, EDARBYCLOR, ELYXYB, ENALAPRIL-HYDROCHLOROTHIAZIDE, ENDOCET, EPITOL, EQUETRO, ESCITALOPRAM OXALATE, ETODOLAC, ETODOLAC ER, EXFORGE HCT, FELDENE, FENOPROFEN CALCIUM, FENOPRON, FENTANYL, FENTANYL CITRATE, FENTANYL CITRATE-0.9% NACL, FENTANYL CITRATE-D5W, FENTANYL CITRATE-STERILE WATER, FENTANYL CITRATE-WATER, FENTANYL-BUPIVACAINE-0.9% NACL, FENTANYL-BUPIVACAINE-NACL, FENTANYL-ROPIVACAINE-0.9% NACL, FENTANYL-ROPIVACAINE-NACL, FIORICET WITH CODEINE, FLUOXETINE DR, FLUOXETINE HCL, FLURBIPROFEN, FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE ER, FOSINOPRIL-HYDROCHLOROTHIAZIDE, HEMICLOR, HYCODAN, HYDROCHLOROTHIAZIDE, HYDROCODONE BITARTRATE, HYDROCODONE BITARTRATE ER, HYDROCODONE-ACETAMINOPHEN, HYDROCODONE-CHLORPHENIRAMNE ER, HYDROCODONE-HOMATROPINE MBR, HYDROCODONE-IBUPROFEN, HYDROMET, HYDROMORPHONE ER, HYDROMORPHONE HCL, HYDROMORPHONE HCL-0.9% NACL, HYDROMORPHONE HCL-D5W, HYDROMORPHONE HCL-NACL, HYDROMORPHONE HCL-WATER, HYSINGLA ER, HYZAAR, IBU, IBUPAK, IBUPROFEN, IBUPROFEN LYSINE, IBUPROFEN-FAMOTIDINE, IMIPRAMINE HCL, IMIPRAMINE PAMOATE, INDAPAMIDE, INDOCIN, INDOMETHACIN, INDOMETHACIN ER, INFLAMMACIN, INFLATHERM(DICLOFENAC-MENTHOL), INFUMORPH, INZIRQO, IRBESARTAN-HYDROCHLOROTHIAZIDE, KETOPROFEN, KETOPROFEN MICRONIZED, KETOROLAC TROMETHAMINE, KIPROFEN, LAMICTAL, LAMICTAL (BLUE), LAMICTAL (GREEN), LAMICTAL (ORANGE), LAMICTAL ODT, LAMICTAL ODT (BLUE), LAMICTAL ODT (GREEN), LAMICTAL ODT (ORANGE), LAMICTAL XR, LAMICTAL XR (BLUE), LAMICTAL XR (GREEN), LAMICTAL XR (ORANGE), LAMOTRIGINE, LAMOTRIGINE (BLUE), LAMOTRIGINE (GREEN), LAMOTRIGINE (ORANGE), LAMOTRIGINE ER, LAMOTRIGINE ODT, LAMOTRIGINE ODT (BLUE), LAMOTRIGINE ODT (GREEN), LAMOTRIGINE ODT (ORANGE), LEVORPHANOL TARTRATE, LEXAPRO, LISINOPRIL-HYDROCHLOROTHIAZIDE, LODINE, LOFENA, LOMOTIL, LOSARTAN-HYDROCHLOROTHIAZIDE, LOTENSIN HCT, LURBIPR, MECLOFENAMATE SODIUM, MEFENAMIC ACID, MELOXICAM, MEPERIDINE HCL, MEPERIDINE HCL-0.9% NACL, METHADONE HCL, METHADONE HCL-0.9% NACL, METHADONE HCL-NACL, METHADONE INTENSOL, METHADOSE, METHYLDOPA-HYDROCHLOROTHIAZIDE, METOLAZONE, METOPROLOL-HYDROCHLOROTHIAZIDE, MICARDIS HCT, MITIGO, MORPHINE SULFATE, MORPHINE SULFATE ER, MORPHINE SULFATE-0.9% NACL, MORPHINE SULFATE-NACL, MOTOFEN, MS CONTIN, NABUMETONE, NABUMETONE MICRONIZED, NALBUPHINE HCL, NALFON, NALOCET, NAPRELAN, NAPROSYN, NAPROTIN, NAPROXEN, NAPROXEN SODIUM, NAPROXEN SODIUM CR, NAPROXEN SODIUM ER, NAPROXEN-ESOMEPRAZOLE MAG, NEOPROFEN, NORPRAMIN, NORTRIPTYLINE HCL, NUCYNTA, NUCYNTA ER, OLANZAPINE-FLUOXETINE HCL, OLMESARTAN-AMLODIPINE-HCTZ, OLMESARTAN-HYDROCHLOROTHIAZIDE, OPIUM TINCTURE, OXAPROZIN, OXYCODONE HCL, OXYCODONE HCL ER, OXYCODONE HYDROCHLORIDE, OXYCODONE-ACETAMINOPHEN, OXYCONTIN, OXYMORPHONE HCL, OXYMORPHONE HCL ER, PAMELOR, PAROXETINE CR, PAROXETINE ER, PAROXETINE HCL, PAROXETINE MESYLATE, PAXIL, PAXIL CR, PENTAZOCINE-NALOXONE HCL, PERCOCET, PERPHENAZINE-AMITRIPTYLINE, PHENYLBUTAZONE, PIROXICAM, PRIMLEV, PROLATE, PROMETHAZINE-CODEINE, PROPRANOLOL-HYDROCHLOROTHIAZID, PROTRIPTYLINE HCL, PROZAC, QDOLO, QUINAPRIL-HYDROCHLOROTHIAZIDE, R.E.C.K.(ROPIV-EPI-CLON-KETOR), RELAFEN DS, REMIFENTANIL HCL, ROPIVACAINE-CLONIDINE-KETOROLC, ROPIVACAINE-KETOROLAC-KETAMINE, ROXICODONE, ROXYBOND, SERTRALINE HCL, SILENOR, SPIRONOLACTONE-HCTZ, SPRIX, SUBLOCADE, SUBOXONE, SUBVENITE, SUBVENITE (BLUE), SUBVENITE (GREEN), SUBVENITE (ORANGE), SUFENTANIL CITRATE, SULINDAC, SUMATRIPTAN SUCC-NAPROXEN SOD, SYMBRAVO, TEGRETOL, TEGRETOL XR, TELMISARTAN-HYDROCHLOROTHIAZID, TENORETIC 100, TENORETIC 50, THALITONE, TOLECTIN 600, TOLMETIN SODIUM, TORONOVA II SUIK, TORONOVA SUIK, TOXICOLOGY SALIVA COLLECTION, TRAMADOL HCL, TRAMADOL HCL ER, TRAMADOL HCL-ACETAMINOPHEN, TRESNI, TREXIMET, TREZIX, TRIAMTERENE-HYDROCHLOROTHIAZID, TRIBENZOR, TRICHLORMETHIAZIDE, TRIMIPRAMINE MALEATE, TUXARIN ER, ULTIVA, VALSARTAN-HYDROCHLOROTHIAZIDE, VASERETIC, VIBERZI, VIMOVO, VIVLODEX, XTAMPZA ER, ZESTORETIC, ZIPSOR, ZOLOFT, ZORVOLEX, ZUBSOLV, ZYNRELEF |
The following contraindication information is available for DDAVP (desmopressin acetate (non-refrigerated)):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 5 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Chronic kidney disease stage 3A (moderate) GFR 45-59 ml/min |
| Chronic kidney disease stage 3B (moderate) GFR 30-44 ml/min |
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
| Hyponatremia |
There are 2 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Kidney disease with likely reduction in glomerular filtration rate (GFr) |
| Psychogenic polydipsia |
There are 5 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Chronic heart failure |
| Coronary artery disease |
| Cystic fibrosis |
| Hypertension |
| Water intoxication |
The following adverse reaction information is available for DDAVP (desmopressin acetate (non-refrigerated)):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 7 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Abnormal hepatic function tests Anaphylaxis Hypertension Hyponatremia Hypotension Seizure disorder Water intoxication |
There are 8 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Abdominal pain with cramps Headache disorder Nausea |
| Rare/Very Rare |
|---|
|
Diarrhea Disturbance in thinking Flushing Vulvodynia Weight gain |
The following precautions are available for DDAVP (desmopressin acetate (non-refrigerated)):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for DDAVP (desmopressin acetate (non-refrigerated)):
WARNING: Desmopressin can rarely cause a low level of sodium in the blood (hyponatremia), which can be serious or even fatal. Drinking too much liquid, using certain medications (such as "water pills"/diuretics including furosemide, corticosteroids such as prednisone), being 65 years or older, or having certain medical conditions may increase the risk of low sodium in the blood. Lab tests (such as urine tests, sodium blood levels) must be done before you start using this medication and while you are using it.
Keep all medical and lab appointments. Tell your doctor right away if you develop symptoms of low sodium in the blood, such as nausea, vomiting, headache, muscle weakness/cramps, unusual tiredness, unusual drowsiness, dizziness, restlessness, mental/mood changes including confusion/irritability. Get medical help right away if you have any very serious side effects, including seizure or trouble breathing.
WARNING: Desmopressin can rarely cause a low level of sodium in the blood (hyponatremia), which can be serious or even fatal. Drinking too much liquid, using certain medications (such as "water pills"/diuretics including furosemide, corticosteroids such as prednisone), being 65 years or older, or having certain medical conditions may increase the risk of low sodium in the blood. Lab tests (such as urine tests, sodium blood levels) must be done before you start using this medication and while you are using it.
Keep all medical and lab appointments. Tell your doctor right away if you develop symptoms of low sodium in the blood, such as nausea, vomiting, headache, muscle weakness/cramps, unusual tiredness, unusual drowsiness, dizziness, restlessness, mental/mood changes including confusion/irritability. Get medical help right away if you have any very serious side effects, including seizure or trouble breathing.
The following icd codes are available for DDAVP (desmopressin acetate (non-refrigerated))'s list of indications:
| Hemophilia A | |
| D66 | Hereditary factor VIII deficiency |
| Z14.02 | Symptomatic hemophilia A carrier |
| Nocturnal enuresis | |
| N39.44 | Nocturnal enuresis |
| Partial central diabetes insipidus | |
| E23.2 | Diabetes insipidus |
| Von willebrand's disease | |
| D68.0 | Von willebrand disease |
| D68.00 | Von willebrand disease, unspecified |
| D68.01 | Von willebrand disease, type 1 |
| D68.02 | Von willebrand disease, type 2 |
| D68.020 | Von willebrand disease, type 2A |
| D68.021 | Von willebrand disease, type 2B |
| D68.022 | Von willebrand disease, type 2M |
| D68.023 | Von willebrand disease, type 2N |
| D68.029 | Von willebrand disease, type 2, unspecified |
| D68.03 | Von willebrand disease, type 3 |
| D68.04 | Acquired von willebrand disease |
| D68.09 | Other von willebrand disease |
Formulary Reference Tool